Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR

NCT03796104 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT03796104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03796104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR
Lead sponsor
Hospices Civils de Lyon
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2018
Completion date
December 31, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone and joint infection, staphylococcus aureus